Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.

Competing Interests: Jorge J. Castillo reports consulting or advisory roles with AbbVie/Pharmacyclics, BeiGene, Cellectar, Janssen, and Roche/Genentech; and research funding from AbbVie, AstraZeneca, Cellectar, LOXO, Pharmacyclics, and TG Therapeutics, outside the submitted work. Mohit Narang reports consulting or advisory roles with BeiGene, Bristol Myers Squibb, Celgene, DSI, and Takeda; and speakers bureau with BeiGene, Bristol Myers Squibb, and Takeda, outside the submitted work. Habte A. Yimer reports stock/stock options from Karyopharm, and speakers bureau with Amgen, AstraZeneca, BeiGene, GSK, Janssen, Karyopharm, Pharmacyclics, and Sanofi, outside the submitted work. Jason M. Melear reports consulting or advisory roles with TG Therapeutics, and speakers bureau with AstraZeneca and BeiGene, outside the submitted work. Morton Coleman reports stocks/stock options from Immunomedics, and receives research funding from AbbVie, BeiGene, Bristol Myers Squibb, Celgene, Genentech, Gilead, InnoCare, Merck, Pfizer, and Roche, outside the submitted work. Charles M. Farber reports stocks/stock options from Alexion; receiving honoraria from Bristol Myers Squibb; consulting or advisory roles with ADC Therapeutics, BeiGene, Gilead, MorphoSys/Incyte, and TG Therapeutics; speakers bureau with ADC Therapeutics, Genentech, Gilead, MorphoSys/Incyte, Seagen, and TG Therapeutics, outside the submitted work. Jonah Shulman reports receiving honoraria from Seagen and TG Therapeutics, and consulting or advisory roles with Seagen and TG Therapeutics, outside the submitted work. Emily H. Mantovani is an employee of BeiGene, with regard to the submitted work, reports former employment with Bristol Myers Squibb, and reports stocks/stock options from BeiGene and Bristol Myers Squibb, outside the submitted work. Xiaowei Zhang and Aileen Cohen are employees of BeiGene, with regards to the submitted work, and report stocks/stock options from BeiGene, outside the submitted work. Jane Huang was an employee of BeiGene at the time of the study, with regards to the submitted work; reports receiving royalties from BeiGene; receiving support for attending meetings and/or travel from BeiGene and Protara; receiving research funding from BeiGene; patents, royalties, or other intellectual property with BeiGene; a leadership role with BeiGene and Protara; and stock/stock options from BeiGene and Roche, outside the submitted work. Edwin C. Kingsley and Constantin A. Dasanu have no relevant disclosures.